Literature DB >> 16885506

Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma.

C Carpentier1, F Laigle-Donadey, Y Marie, N Auger, A Benouaich-Amiel, J Lejeune, G Kaloshi, J-Y Delattre, J Thillet, M Sanson.   

Abstract

We investigated two polymorphisms of the epidermal growth factor receptor promoter as potential risk factors and prognostic markers for glioblastoma. The -216T allele (which results in a 30% higher activity) was more frequent in the patients compared with the control population (224/376 = 59.6% vs 165/352 = 46.8%; p = 0.0006) corresponding to an odd ratio of 1.67 (1.24; 2.25). A modest difference in median survival was also associated with the TT genotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885506     DOI: 10.1212/01.wnl.0000229927.12007.37

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Molecular epidemiology of primary brain tumors.

Authors:  Jun Gu; Yanhong Liu; Athanassios P Kyritsis; Melissa L Bondy
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Authors:  Ranbir Chander Sobti; Marjan Askari; Mohsen Nikbakht; Neha Singh; Suresh C Sharma; Abayneh Munshea Abitew
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

3.  Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.

Authors:  Shaoyi Li; Wenchang Guo; Yun Gao; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-11-28

4.  Survival and low-grade glioma: the emergence of genetic information.

Authors:  Elizabeth B Claus; Kyle M Walsh; John K Wiencke; Annette M Molinaro; Joseph L Wiemels; Joellen M Schildkraut; Melissa L Bondy; Mitchel Berger; Robert Jenkins; Margaret Wrensch
Journal:  Neurosurg Focus       Date:  2015-01       Impact factor: 4.047

5.  Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma.

Authors:  Jin Chen; Qin Huang; Feng Wang
Journal:  Tumour Biol       Date:  2014-04-27

6.  EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.

Authors:  Shaoyi Li; Yun Gao; Weining Ma; Wenchang Guo; Gang Zhou; Tianci Cheng; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-02-21

7.  Inherited variation in immune genes and pathways and glioblastoma risk.

Authors:  Judith A Schwartzbaum; Yuanyuan Xiao; Yanhong Liu; Spyros Tsavachidis; Mitchel S Berger; Melissa L Bondy; Jeffrey S Chang; Susan M Chang; Paul A Decker; Bo Ding; Sarah J Hepworth; Richard S Houlston; Fay J Hosking; Robert B Jenkins; Matthew L Kosel; Lucie S McCoy; Patricia A McKinney; Kenneth Muir; Joe S Patoka; Michael Prados; Terri Rice; Lindsay B Robertson; Minouk J Schoemaker; Sanjay Shete; Anthony J Swerdlow; Joe L Wiemels; John K Wiencke; Ping Yang; Margaret R Wrensch
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

8.  A two-stage case-control study of EGFR polymorphisms and breast cancer risk.

Authors:  Young-Seoub Hong; Sandra L Deming; Yu-Tang Gao; Ji-Rong Long; Xiao-Ou Shu; Qiuyin Cai; Wei Lu; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

9.  Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.

Authors:  Jin Eun Choi; Sun Ha Park; Kyung Mee Kim; Won Kee Lee; Sin Kam; Sung Ick Cha; Chang Ho Kim; Young Mo Kang; Young-Chul Kim; Sung Beom Han; Tae Hoon Jung; Jae Yong Park
Journal:  BMC Cancer       Date:  2007-10-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.